Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party
Authors
Keywords
-
Journal
CANCER
Volume 125, Issue 1, Pages 90-98
Publisher
Wiley
Online
2018-10-24
DOI
10.1002/cncr.31755
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party
- (2018) Ali Bazarbachi et al. BRITISH JOURNAL OF HAEMATOLOGY
- The Role of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphoma
- (2017) Leona Holmberg et al. Journal of the National Comprehensive Cancer Network
- Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation
- (2016) P Tsirigotis et al. BONE MARROW TRANSPLANTATION
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brentuximab Vedotin in Patients With Hodgkin Lymphoma and a Failed Allogeneic Stem Cell Transplantation: Results From a Named Patient Program at Four Italian Centers
- (2015) C. Carlo-Stella et al. ONCOLOGIST
- Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
- (2014) A. K. Gopal et al. BLOOD
- Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!
- (2014) M A Kharfan-Dabaja et al. BONE MARROW TRANSPLANTATION
- Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi
- (2014) Antonella Anastasia et al. BRITISH JOURNAL OF HAEMATOLOGY
- Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
- (2014) Nancy L Bartlett et al. Journal of Hematology & Oncology
- Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation†
- (2013) C. Martínez et al. ANNALS OF ONCOLOGY
- Expression of CD30 in patients with acute graft-versus-host disease
- (2012) Y.-B. Chen et al. BLOOD
- Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation
- (2012) A. K. Gopal et al. BLOOD
- Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma
- (2012) Gaetano Corazzelli et al. BRITISH JOURNAL OF HAEMATOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Histology and Time to Progression Predict Survival for Lymphoma Recurring after Reduced-Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation
- (2011) Ron Ram et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability
- (2010) B. Sarina et al. BLOOD
- Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma
- (2009) Alison J. Moskowitz et al. BRITISH JOURNAL OF HAEMATOLOGY
- Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non-Hodgkin Lymphoma: Importance of Histology for Outcome
- (2008) Philippe Armand et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience
- (2008) P. Anderlini et al. HAEMATOLOGICA
- Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome
- (2008) S. P. Robinson et al. HAEMATOLOGICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started